Wikisage, the free encyclopedia of the second generation, is digital heritage
Belzutifan: Difference between revisions
Jump to navigation
Jump to search
(→ATC: File:Buecher_Regal_636.jpg) |
(→ATC) |
||
| Line 5: | Line 5: | ||
Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)<ref>https://en.wikipedia.org/wiki/Medicines_and_Healthcare_products_Regulatory_Agency</ref> | Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)<ref>https://en.wikipedia.org/wiki/Medicines_and_Healthcare_products_Regulatory_Agency</ref> | ||
==ATC== | ==[[ATC]]== | ||
none | |||
{| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | |||
|colspan=2| <center>[[File:Belzutifan.png|92px]] | |||
: [[wikipedia:belzutifan|belzutifan]] </center> | |||
|} | |||
[[File:Buecher_Regal_636.jpg|32px]] | [[File:Buecher_Regal_636.jpg|32px]] | ||
Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs<ref>Dictionary of Medical eponyms</ref> | Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs<ref>Dictionary of Medical eponyms</ref> | ||
{{wikidata|Q27456641}} | {{wikidata|Q27456641}} | ||
Revision as of 23:28, 13 August 2021
Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.
Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).
Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)[1]
ATC
none
|
Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs[2]
- ↑ https://en.wikipedia.org/wiki/Medicines_and_Healthcare_products_Regulatory_Agency
- ↑ Dictionary of Medical eponyms